Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients*
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objective: Candida species represent the fourth cause of nosocomial bloodstream infections worldwide. Because Candida glabrata has become the second most frequently identified yeast and because the rate of fluconazole-resistant C. glabrata strains reaches 10% to 15%, initial antifungal therapy based on fluconazole in nonneutropenic hemodynamically stable patients, as recommended by current guidelines, may be an ineffective option. Our aim was to determine easy-to-identify risk factors for C. glabrata fungemia likely to guide and improve initial antifungal therapy. Design: Prospective multicenter cohort study. Setting: Five French intensive care units. Patients: Consecutive nonneutropenic patients without known Candida colonization who had blood culture-confirmed fungemia over a 4-yr period. Interventions: None. Measurements and Main Results: A total of 8206 patients were screened. One hundred fifty-four patients with blood culture-confirmed fungemia constituted the cohort, of whom 48 had C. glabrata fungemia and 106 had nonglabrata fungemia. Patients' baseline characteristics and in-intensive care unit events potentially related to C. glabrata fungemia were systematically recorded. Compared with patients with nonglabrata fungemia, patients with C. glabrata fungemia were older and more severely ill, had received more antibiotics, and were more likely to have undergone surgery. The stepwise logistic regression analysis identified six independent risk factors for C. glabrata fungemia: age >60 yrs, recent abdominal surgery, interval from intensive care unit admission to first positive blood culture ≤7 days, recent use of cephalosporins, solid tumor, and absence of diabetes mellitus. The model showed satisfying goodness of fit (Hosmer-Lemeshow statistic = .26) and discrimination (c statistic = .89). Conclusions: We found six early available and easy-to-identify risk factors for C. glabrata fungemia. When these factors are present, alternatives to fluconazole for initial antifungal therapy should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“Crude mortality is nearly 50%, with some variations among available series probably reflecting differences in underlying severity (2), and attributable mortality is estimated to be 15% to 25% in adult patients (10).”
BackgroundGuidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 2×
“glabrata strains reaches 10% to 15% (13), this therapeutic option may be ineffective and may result in subsequent poorer prognosis.”
BackgroundSecular trends in nosocomial primary bloodstream infections in the United States, 1980–1989.
Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90349-3 · Cited by 880
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance
Krcmery, V., & Barnes, A. J. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1151 · Cited by 733
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Risk Factors for Hospital-Acquired Candidemia: A Matched Case-Control Study
Wey, S. B. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100145030 · Cited by 369
Nguyen, M. H. (1995) · Archives of Internal Medicine · doi:10.1001/archinte.1995.00430220087009 · Cited by 363
Nolla-Salas, J., Sitges-Serra, A., León-Gil, C., Martínez-González, J., León-Regidor, M. A., Ibán˜ez-Lucí, P., & Torres-Rodríguez, J. M. (1997) · Intensive Care Medicine · doi:10.1007/s001340050286 · Cited by 263
Effects of nosocomial candidemia on outcomes of critically ill patients
Blot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01248-2 · Cited by 235
Cited by
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Pfaller, M. A., Messer, S. A., Moet, G. J., Jones, R. N., & Castanheira, M. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.02.016 · Cited by 274
Roetzer, A., Gabaldón, T., & Schüller, C. (2011) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02102.x · Cited by 154
“Here, we discuss the properties of C. glabrata with a focus on the differences to related fungi.”
Background
Metadata
- Authors
- Cohen, Y., Karoubi, P., Adrie, C., Gauzit, R., Marsepoil, T., Zarka, D., & Clecʼh, C.
- Venue
- Critical Care Medicine
- Published
- 2010-03
- Volume
- 38
- Issue
- 3
- Pages
- 826-830
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2083058613
- Cited by
- 48
- References
- 12
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients*. https://app.cochat.ai/papers/10.1097/ccm.0b013e3181cc4734
- The paper
- Cohen, Y., Karoubi, P., Adrie, C., Gauzit, R., Marsepoil, T., Zarka, D., & Clecʼh, C. (2010). Early prediction of Candida glabrata fungemia in nonneutropenic critically ill patients*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e3181cc4734
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.